Camrelizumab Combined With Radiotherapy for Adjuvant Treatment of Esophageal Squamous Cell Carcinoma After Surgery

NCT04741490 · clinicaltrials.gov ↗

NA

Phase

UNKNOWN

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Esophageal Squamous Cell Carcinomas

Interventions

DRUG: Camrelizumab
RADIATION: radiotherapy

Sponsor

Fuzhou General Hospital